{"text": "There were 14 in-hospital deaths without relationship to GLN administration.", "user_data": {"pmid": "10338217"}}
{"text": "For respective comparisons of ALLO and AUTO transplants in the GLN and GLY hematologic groups and AUTO in the solid tumor groups, there were no significant differences in hospital stay, duration of stay after BMT, TPN days, neutrophil recovery >500/mm3, incidence of positive blood cultures, sepsis, mucositis, and diarrhea.", "user_data": {"pmid": "10338217"}}
{"text": "Acute graft us host disease occurred in 1 of 10 hematologic patients receiving GLN and in 3 of 8 patients receiving GLY placebo (p > .05).", "user_data": {"pmid": "10338217"}}
{"text": "Possible reduction in need for TPN and a suggestion of improved long-term survival were associated with GLN.", "user_data": {"pmid": "10338217"}}
{"text": "Compared with before priming, after priming the times to neutrophil nadir (12.8 +/- 2.5 days v 14.8 +/- 1.5 days, respectively; P =.0001) and platelet nadir (mean +/- SD, 10.1 +/- 1.9 days v 11.1 +/- 2.2 days, P <.05) were shorter, indicating a shift of cytotoxicity to later progenitors.", "user_data": {"pmid": "10550137"}}
{"text": "The neutrophil nadir was similar with and without priming (mean +/- SD, 490 +/- 310/microL v 550 +/- 350/microL, respectively; P =.2); however, on day 16 the mean neutrophil count was higher (mean +/- SD, 1030 +/- 580/microL v 690 +/- 370/microL, P =.004), and the proportion of patients with a neutrophil count less than 500/microL was lower after priming than before (six of 35 or 17.", "user_data": {"pmid": "10550137"}}
{"text": "1% v 12 of 34 or 35.3%, respectively; P =.04).", "user_data": {"pmid": "10550137"}}
{"text": "The platelet nadir was higher (mean +/- SD, 166,000 +/- 51,000/microL after priming v 151,000 +/- 45,000/microL before priming, P =.007), and the duration of thrombocytopenia, ie, a platelet count less than 150,000/microL, was shorter (1.5 +/- 2.1 days v 2.8 +/- 2.9 days, P =.0025) after priming.", "user_data": {"pmid": "10550137"}}
{"text": "Episodes of fever and neutropenia were not observed.", "user_data": {"pmid": "10550137"}}
{"text": "The response rates (complete response and partial response) of patients who received CAF and CAFTH were similar (69.2% v 68.9%, respectively; P =.99).", "user_data": {"pmid": "10637238"}}
{"text": "Time to treatment failure (TTF) was slightly longer for patients who received chemohormonal therapy compared with chemotherapy alone patients (13.4 months v 10.3 months, respectively; P =.087), and TTF was significantly longer in ER-positive compared with ER-negative patients (17.4 months v 10.3 months, respectively; P =.048).", "user_data": {"pmid": "10637238"}}
{"text": "However, ER status had no effect on overall survival (30.0 months for CAF v 29.3 months for CAFTH).", "user_data": {"pmid": "10637238"}}
{"text": "Hematologic toxicity was similar.", "user_data": {"pmid": "10963640"}}
{"text": "Nausea/vomiting and stomatitis were significantly less frequent in arm A as was left ventricular ejection fraction decrease in arm C (A = six patients, B = five patients, and C = one patient).", "user_data": {"pmid": "10963640"}}
{"text": "Six patients died of infections (A = four patients and C = two patients).", "user_data": {"pmid": "10963640"}}
{"text": "After four cycles, the objective response rate (ORR) was better with FEC 100 than with FEC 75 (49.2% v 40%, respectively; P: =.07).", "user_data": {"pmid": "10963640"}}
{"text": "The ORR was better with the longer regimens (arm A, 56.9%; B, 64%; and C, 47.6%; P: =.06) and was 41% after second-line FEC 100.", "user_data": {"pmid": "10963640"}}
{"text": "After a median follow-up of 41 months, the response duration and time to progression (TTP) were significantly better with arm B, the longer regimen (P: =.012 and P: < 10(-3), respectively).", "user_data": {"pmid": "10963640"}}
{"text": "The median survival times for arms A, B, and C were similar (17.9, 18.9, and 16.3 months, respectively; P: =.49).", "user_data": {"pmid": "10963640"}}
{"text": "In group A with 90 evaluable patients, the response rate was 25.6% (6 CR, 17 PR) whereas in group B with 88 evaluable patients, the response rate was 31.8% (3 CR, 25 PR), P = 0.733.", "user_data": {"pmid": "10997806"}}
{"text": "Median time to progression favored the high-dose paclitaxel (4.3 vs. 6.4 months, P = 0.044).", "user_data": {"pmid": "10997806"}}
{"text": "The median survival was 9.5 months for group A versus 11.4 months for group B (P = 0.16).", "user_data": {"pmid": "10997806"}}
{"text": "The one-year survival was 37% for group A and 44% for group B (P = 0.35).", "user_data": {"pmid": "10997806"}}
{"text": "The best prognostic factor for one-year survival was the response rate (P < 0.0001).", "user_data": {"pmid": "10997806"}}
{"text": "With a relative dose intensity of paclitaxel 0.94 in both groups, neurotoxicity (P = 0.025) and leucopenia (P = 0.038) were more pronounced in group B patients.", "user_data": {"pmid": "10997806"}}
{"text": "No toxic death was observed.", "user_data": {"pmid": "10997806"}}
{"text": "Compared with the cisplatin-only arm, there was a 9% improvement (95% confidence interval, 0% to 19%) in overall response rate for the paclitaxel/cisplatin arm (17% v 26%, respectively; P=.028).", "user_data": {"pmid": "11013280"}}
{"text": "Median time to progression was 2.7 and 4.1 months in the control and paclitaxel/cisplatin arm, respectively (P=.026).", "user_data": {"pmid": "11013280"}}
{"text": "The study, however, failed to show a significant improvement in median survival for the paclitaxel/cisplatin arm (8.6 months in the control arm v 8.1 months in the paclitaxel/cisplatin arm, P=.862).", "user_data": {"pmid": "11013280"}}
{"text": "There was more hematotoxicity, peripheral neuropathy, and arthralgia/myalgia on the paclitaxel/cisplatin arm, whereas the high-dose cisplatin arm produced more ototoxicity, nausea, vomiting, and nephrotoxicity.", "user_data": {"pmid": "11013280"}}
{"text": "Quality of life (QOL) was similar overall between the two arms.", "user_data": {"pmid": "11013280"}}
{"text": "One hundred twenty eligible patients were randomized.", "user_data": {"pmid": "11013281"}}
{"text": "A 57% response rate was seen in the combined-modality arm (95% confidence interval [CI], 43% to 69%), and a 22% response rate was seen in the teniposide-alone arm (95% CI, 12% to 34%) (P<.001).", "user_data": {"pmid": "11013281"}}
{"text": "Time to progression in the brain was longer in the combined-modality group (P=.005).", "user_data": {"pmid": "11013281"}}
{"text": "Clinical response and response outside the brain were not different.", "user_data": {"pmid": "11013281"}}
{"text": "The median survival time was 3.5 months in the combined-modality arm and 3.2 months in the teniposide-alone arm.", "user_data": {"pmid": "11013281"}}
{"text": "Overall survival in both groups was not different (P=.087).", "user_data": {"pmid": "11013281"}}
{"text": "Cardiovascular event rates were not statistically significantly different between women assigned to receive tamoxifen and those assigned to receive placebo, independent of pre-existing CHD.", "user_data": {"pmid": "11136837"}}
{"text": "Among women without CHD (6074 on tamoxifen versus 6072 on placebo), risk ratios (95% confidence intervals [CIs]) for tamoxifen users were 1.75 (0.44 to 8.13) for fatal myocardial infarction, 1.11 (0.55 to 2.28) for nonfatal myocardial infarction, 0.69 (0.29 to 1.57) for unstable angina, and 0.83 (0.32 to 2.10) for severe angina.", "user_data": {"pmid": "11136837"}}
{"text": "In women with CHD (516 on tamoxifen versus 532 on placebo), risk ratios (95% CIs) for tamoxifen users were 0.00 (0 to 1.58) for fatal myocardial infarction, 1.25 (0.32 to 5.18) for nonfatal myocardial infarction, 2.26 (0.87 to 6.55) for unstable angina, and 1.39 (0.23 to 9.47) for severe angina.", "user_data": {"pmid": "11136837"}}
{"text": "There was no evidence that the lack of association between tamoxifen and cardiovascular events was related to an early increase in risk that may have been offset by a late decrease in risk.", "user_data": {"pmid": "11136837"}}
{"text": "A total of 474 patients were treated (239 PLD and 235 topotecan).", "user_data": {"pmid": "11454878"}}
{"text": "They comprised the intent-to-treat population.", "user_data": {"pmid": "11454878"}}
{"text": "The overall progression-free survival rates were similar between the two arms (P =.095).", "user_data": {"pmid": "11454878"}}
{"text": "The overall response rates for PLD and topotecan were 19.7% and 17.0%, respectively (P =.390).", "user_data": {"pmid": "11454878"}}
{"text": "Median overall survival times were 60 weeks for PLD and 56.7 weeks for topotecan.", "user_data": {"pmid": "11454878"}}
{"text": "Data analyzed in platinum-sensitive patients demonstrated a statistically significant benefit from PLD for progression-free survival (P =.037), with medians of 28.9 for PLD versus 23.3 weeks for topotecan.", "user_data": {"pmid": "11454878"}}
{"text": "For overall survival, PLD was significantly superior to topotecan (P =.008), with a median of 108 weeks versus 71.1 weeks.", "user_data": {"pmid": "11454878"}}
{"text": "The platinum-refractory subgroup demonstrated a nonstatistically significant survival trend in favor of topotecan (P =.455).", "user_data": {"pmid": "11454878"}}
{"text": "Severe hematologic toxicity was more common with topotecan and was more likely to be associated with dosage modification, or growth factor or blood product utilization.", "user_data": {"pmid": "11454878"}}
{"text": "Median age was 54 years in both treatment groups.", "user_data": {"pmid": "11815957"}}
{"text": "All relevant prognostic factors were balanced, with the exception that there were significantly more progesterone receptor positive patients in the doxorubicin-treated group.", "user_data": {"pmid": "11815957"}}
{"text": "Protocol-defined cardiotoxicity was observed in 13% of TLC D-99 patients (including 2 cases of CHF) compared to 29% of doxorubicin patients (including 9 cases of CHF).", "user_data": {"pmid": "11815957"}}
{"text": "Median cumulative doxorubicin dose at onset of cardiotoxicity was 785 mg/m(2) for TLC D-99 versus 570 mg/m(2) for doxorubicin (P = 0.0001; hazard ratio, 3.56).", "user_data": {"pmid": "11815957"}}
{"text": "The overall response rate was 26% in both treatment groups.", "user_data": {"pmid": "11815957"}}
{"text": "The median TTP was 2.9 months on TLC D-99 versus 3.1 months on doxorubicin.", "user_data": {"pmid": "11815957"}}
{"text": "Median survival was 16 versus 20 months with a nonsignificant trend in favor of doxorubicin (P = 0.09).", "user_data": {"pmid": "11815957"}}
{"text": "Clinical toxicities, commonly associated with doxorubicin, appeared less common with TLC D-99, although the difference was not statistically significant.", "user_data": {"pmid": "11815957"}}
{"text": "There was only one report of palmar-plantar erythrodysesthesia (Grade 2) with this liposomal formulation of doxorubicin.", "user_data": {"pmid": "11815957"}}
{"text": "Standard histopathological analysis revealed no lymph node involvement (pN0) in 61 patients, pN1 disease in 13 patients and pN2 disease in 20 patients without significant differences between LA and LS with respect to T-stage, N-stage or age and sex of the patients.", "user_data": {"pmid": "11888774"}}
{"text": "By immunohistochemistry a minimal nodal spread of tumor cells was detected in 21 out of 94 patients (LS, n=10 (24%); LA, n=11 (21%)).", "user_data": {"pmid": "11888774"}}
{"text": "Similar to the entire group of patients also in the subset of patients with nodal micrometastases the type of lymphadenectomy did not significantly influence the long-term survival (P=0.27 and P=0.39, respectively).", "user_data": {"pmid": "11888774"}}
{"text": "In contrast, in patients with a negative immunohistochemical analysis systematic lymphadenectomy resulted in an improved overall survival (P=0.044).", "user_data": {"pmid": "11888774"}}
{"text": "Serum-free estradiol and estrone levels decreased moderately in the experimental group.", "user_data": {"pmid": "11920488"}}
{"text": "Serum hormone-binding globulin levels increased in 41.4% of women in the experimental group compared with 37.5% of women in the placebo group.", "user_data": {"pmid": "11920488"}}
{"text": "Free estradiol decreased in 53.85% of women in the experimental group compared with 37.5% of women in the placebo group.", "user_data": {"pmid": "11920488"}}
{"text": "Estrone decreased in 55.56% of women in the experimental group compared with 42.86% in the placebo group.", "user_data": {"pmid": "11920488"}}
{"text": "Those women in the experimental group who were consuming soy had their mean menstrual cycle length increased by 3.52 days compared with a mean decrease of 0.06 days for women in the placebo group (P = 0.04) from baseline to the third menstrual cycle.", "user_data": {"pmid": "11920488"}}
{"text": "In addition, women who were taking soy had their mean follicular phase increase by 1.46 days compared with a mean increase of 0.14 days for women who were taking the placebo (P = 0.08).", "user_data": {"pmid": "11920488"}}
{"text": "Patients in group C had a significantly reduced need for propofol (P < 0.04) and sevoflurane (P < 0.01) and a reduced early need for ketobemidone (P < 0.04).", "user_data": {"pmid": "11981150"}}
{"text": "There were significantly more PONV-free patients in group C compared with group P (20 and 11 of 30, respectively; P < 0.04).", "user_data": {"pmid": "11981150"}}
{"text": "The number needed to treat was 3.3 (95% confidence interval, 1.8, 16.9).", "user_data": {"pmid": "11981150"}}
{"text": "Intraoperative blood pressure, postoperative heart rate, and postoperative blood pressure were all significantly lower in group C compared with group P, but were not considered to be of clinical importance.", "user_data": {"pmid": "11981150"}}
{"text": "No negative side effects were recorded.", "user_data": {"pmid": "11981150"}}
{"text": "Capecitabine/docetaxel resulted in significantly superior efficacy in time to disease progression (TTP) (hazard ratio, 0.652; 95% confidence interval [CI], 0.545 to 0.780; P =.0001; median, 6.1 v 4.2 months), overall survival (hazard ratio, 0.775; 95% CI, 0.634 to 0.947; P =.0126; median, 14.5 v 11.5 months), and objective tumor response rate (42% v 30%, P =.006) compared with docetaxel.", "user_data": {"pmid": "12065558"}}
{"text": "Gastrointestinal side effects and hand-foot syndrome were more common with combination therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more common with single-agent docetaxel.", "user_data": {"pmid": "12065558"}}
{"text": "More grade 3 adverse events occurred with combination therapy (71% v 49%, respectively), whereas grade 4 events were slightly more common with docetaxel (31% v 25% with combination).", "user_data": {"pmid": "12065558"}}
{"text": "Circulating tumour cells were detected and monitored throughout treatment periods.", "user_data": {"pmid": "12116339"}}
{"text": "An initial rise in circulating cells after the first cycle was followed by a fall in both treatment arms to baseline levels set by normal controls.", "user_data": {"pmid": "12116339"}}
{"text": "This was achieved by week 12 in the accelerated treatment arm and by week 24 in the standard arm.", "user_data": {"pmid": "12116339"}}
{"text": "At week 6, hot flashes were reduced by 86% on average in the whole group of patients, without significant differences between the two progestins.", "user_data": {"pmid": "12123333"}}
{"text": "Response was obtained by 75 and 67% of patients receiving MPA or megestrol, respectively (P = 0.5).", "user_data": {"pmid": "12123333"}}
{"text": "Responders were followed to assess maintenance of response (without further treatment), which was significantly better with i.m. MPA: in this group, 89% of responders still showed a benefit at week 24, compared with 45% in the megestrol group (P = 0.03).", "user_data": {"pmid": "12123333"}}
{"text": "Analyses of self-reported daily activity levels revealed a diffusion of treatment effect.", "user_data": {"pmid": "12406050"}}
{"text": "Fifty percent of the usual-care group reported maintaining or increasing their physical activity to a moderate-intensity level, while 33% of the exercise group did not exercise at the prescribed levels.", "user_data": {"pmid": "12406050"}}
{"text": "Analyses of self-reported disease symptoms and treatment side effects did not reveal clinically meaningful differences between the two groups.", "user_data": {"pmid": "12406050"}}
{"text": "With a median follow-up of 59.5 months, WP RT was associated with a 4-year PFS of 54% compared with 47% in patients treated with PO RT (P =.022).", "user_data": {"pmid": "12743142"}}
{"text": "Patients treated with NCHT experienced a 4-year PFS of 52% versus 49% for AHT (P =.56).", "user_data": {"pmid": "12743142"}}
{"text": "When comparing all four arms, there was a progression-free difference among WP RT + NCHT, PO RT + NCHT, WP RT + AHT, and PO RT + AHT (60% v 44% v 49% v 50%, respectively; P =.008).", "user_data": {"pmid": "12743142"}}
{"text": "No survival advantage has yet been seen.", "user_data": {"pmid": "12743142"}}
{"text": "Response rates in the 20 mg arm were numerically higher than the 50-mg arm according to the investigator (40.5% versus 36.4%) and the independent review panel (42.9% versus 27.3%).", "user_data": {"pmid": "12954577"}}
{"text": "CBR was higher in the 20 mg arm according to the investigator (64.3% versus 61.4%) and the independent review panel (59.5% versus 47.7%).", "user_data": {"pmid": "12954577"}}
{"text": "Arzoxifene was well tolerated.", "user_data": {"pmid": "12954577"}}
{"text": "There were no study drug-related deaths.", "user_data": {"pmid": "12954577"}}
{"text": "Mean observed steady-state plasma concentrations of arzoxifene were 3.62 and 7.48 ng/ml for the 20 and 50 mg doses, respectively.", "user_data": {"pmid": "12954577"}}
{"text": "A total of 226 patients were evaluable for response.", "user_data": {"pmid": "14679127"}}
{"text": "Demographic characteristics were similar in both treatment groups, as were results of the EORTC QOL-30 questionnaire.", "user_data": {"pmid": "14679127"}}
{"text": "For the topotecan group, median time to progression was 18.9 weeks (range <1 to 92.6+ weeks; 25% censored), and, for paclitaxel, 14.7 weeks (range <1 to 137.3+ weeks; 12.3% censored); P = 0.076.", "user_data": {"pmid": "14679127"}}
{"text": "At 4 years post-randomisation, median survival in the topotecan group was 63.0 weeks (range <1 to 238.4+ weeks; 20.5% censored) and, for paclitaxel, 53.0 weeks (range <1 to 226.3+ weeks; 12.3% censored); P = 0.44.", "user_data": {"pmid": "14679127"}}
{"text": "PLD and doxorubicin were comparable with respect to PFS [6.9 versus 7.8 months, respectively; hazard ratio (HR)=1.00; 95% confidence interval (CI) 0.82-1.22].", "user_data": {"pmid": "14998846"}}
{"text": "Subgroup results were consistent.", "user_data": {"pmid": "14998846"}}
{"text": "Overall risk of cardiotoxicity was significantly higher with doxorubicin than PLD (HR=3.16; 95%CI 1.58-6.31; P<0.001).", "user_data": {"pmid": "14998846"}}
{"text": "Overall survival was similar (21 and 22 months for PLD and doxorubicin, respectively; HR=0.94; 95%CI 0.74-1.19).", "user_data": {"pmid": "14998846"}}
{"text": "Alopecia (overall, 66% versus 20%; pronounced, 54% versus 7%), nausea (53% versus 37%), vomiting (31% versus 19%) and neutropenia (10% versus 4%) were more often associated with doxorubicin than PLD.", "user_data": {"pmid": "14998846"}}
{"text": "Palmar-plantar erythrodysesthesia (48% versus 2%), stomatitis (22% versus 15%) and mucositis (23% versus 13%) were more often associated with PLD than doxorubicin.", "user_data": {"pmid": "14998846"}}
{"text": "Chemotherapy was given before surgery in 3% of patients whilst 97% received adjuvant chemotherapy.", "user_data": {"pmid": "15200998"}}
{"text": "Baseline characteristics were: median age 61 years, 69% male, 48% squamous cell, 93% WHO PS 0-1, 27% stage I, 38% stage II, and 34% stage III.", "user_data": {"pmid": "15200998"}}
{"text": "Complete resection was achieved in approximately 95% of patients.", "user_data": {"pmid": "15200998"}}
{"text": "In the C group, 13% received no chemotherapy, 21% one or two cycles, and 64% all three cycles of their prescribed chemotherapy (60% of the latter with no delays or modification).", "user_data": {"pmid": "15200998"}}
{"text": "30% had grade 3/4 toxicity, mainly haematological, nausea/vomiting and neutropenic fever, and six patients were reported as having a treatment-related death.", "user_data": {"pmid": "15200998"}}
{"text": "198 (52%) of patients have died, but there is currently no evidence of a benefit in overall survival to the C group: HR 1.02 (95% CI 0.77-1.35), P = 0.90).", "user_data": {"pmid": "15200998"}}
{"text": "308 patients were included in this trial with 156 patients in group 1 and 152 in group 2.", "user_data": {"pmid": "15217131"}}
{"text": "Group 1 experienced statistically less pain for VAS 1 (0.1 versus 1.4, p < 0.0001) and VAS 3 (0.8 versus 1.4, p < 0.001) but no significative difference could be demonstrated for VAS 2 (1.8 versus 2.0).", "user_data": {"pmid": "15217131"}}
{"text": "No major complication was noted.", "user_data": {"pmid": "15217131"}}
{"text": "There was significantly less blood lost in the tourniquet group than in the control group (difference between means 1870 mL, 95% CI 1159-2580 mL, P < 0.0001; transfusion rates of 7% and 79%, P= 0.0003).", "user_data": {"pmid": "15713151"}}
{"text": "The volume in the pelvic drain 20 min post-operatively and after 48 hours failed to reach statistical significance between the two groups (P= 0.10 and P= 0.165).", "user_data": {"pmid": "15713151"}}
{"text": "There were no differences in uterine artery Doppler resistance indices at five days (P= 0.54), six weeks (P= 0.47), three months (P= 0.49) and at six months (P= 0.18).", "user_data": {"pmid": "15713151"}}
{"text": "Day two serum FSH concentrations after surgery were unchanged (P= 0.45), compared with baseline values.", "user_data": {"pmid": "15713151"}}
{"text": "Between December 2001 and October 2003, 92 patients were enrolled and randomly assigned to treatment with ixabepilone alone (45 patients) or in combination with EMP (47 patients).", "user_data": {"pmid": "15735119"}}
{"text": "Grades 3 and 4 toxicities experienced by more than 5% of patients included neutropenia (22%), fatigue (9%), and neuropathy (13%) on the ixabepilone arm, and neutropenia (29%), febrile neutropenia (9%), fatigue (9%), neuropathy (7%), and thrombosis (6%) on the ixabepilone + EMP arm.", "user_data": {"pmid": "15735119"}}
{"text": "Post-treatment declines in prostate-specific antigen of > or = 50% were achieved in 21 of 44 patients (48%; 95% CI, 33% to 64%) on the ixabepilone arm, and 31 of 45 patients (69%; 95% CI, 55% to 82%) on the ixabepilone + EMP arm.", "user_data": {"pmid": "15735119"}}
{"text": "In patients with measurable disease, partial responses were observed in eight of 25 patients (32%; 95% CI, 14% to 50%) on the ixabepilone arm, and 11 of 23 (48%; 95% CI, 27% to 68%) on the ixabepilone + EMP arm.", "user_data": {"pmid": "15735119"}}
{"text": "Time to prostate-specific antigen progression was 4.4 months (95% CI, 3.1 to 6.9 months) on the ixabepilone-alone arm and 5.2 months (95% CI, 4.5 to 6.8 months) on the combination arm.", "user_data": {"pmid": "15735119"}}
{"text": "The SRE rate ratio at 1 year (excluding HCM and adjusted for prior fracture) was 0.61 (permutation test; P = .027), indicating that zoledronic acid reduced the rate of SRE by 39% compared with placebo.", "user_data": {"pmid": "15738536"}}
{"text": "The percentage of patients with at least one SRE (excluding HCM) was significantly reduced by 20% by zoledronic acid (29.8% v 49.6% for placebo; P = .003).", "user_data": {"pmid": "15738536"}}
{"text": "Zoledronic acid significantly delayed time-to-first SRE (median not reached v 364 days; Cox regression; P = .007) and reduced the risk of SREs by 41% in multiple event analysis (risk ratio = 0.59; P = .019) compared with placebo.", "user_data": {"pmid": "15738536"}}
{"text": "Zoledronic acid was well tolerated with a safety profile similar to placebo.", "user_data": {"pmid": "15738536"}}
{"text": "No patient treated with zoledronic acid had grade 3 or 4 serum creatinine increase.", "user_data": {"pmid": "15738536"}}
{"text": "Seventy patients completed the study (36 verum; 34 placebo).", "user_data": {"pmid": "15774238"}}
{"text": "Compliance was >90% in all patients.", "user_data": {"pmid": "15774238"}}
{"text": "In the intervention group, plasma levels of vitamin E, selenium and coenzyme Q10 increased significantly over the 21 weeks study period.", "user_data": {"pmid": "15774238"}}
{"text": "No significant differences in serum levels of PSA, testosterone, dihydrotestosterone, luteinizing hormone or sex hormone binding globulin (p>0.2) were observed between the intervention and control group.", "user_data": {"pmid": "15774238"}}
{"text": "Of 141 patients enrolled, 83% were randomly assigned after chemotherapy to qdRT (n = 59) or HART (n = 60).", "user_data": {"pmid": "15837967"}}
{"text": "Median survival was 20.3 and 14.9 months for HART and qdRT, respectively (P = .28).", "user_data": {"pmid": "15837967"}}
{"text": "Overall response was 25% and 22% for HART and qdRT, respectively (P = .69).", "user_data": {"pmid": "15837967"}}
{"text": "Two- and 3-year survival was 44% and 34% for HART, and 24% and 14% for qdRT, respectively.", "user_data": {"pmid": "15837967"}}
{"text": "Grade > or = 3 toxicities included esophagitis in 14 v nine patients, and pneumonitis in 0 v 6 patients for HART and qdRT, respectively.", "user_data": {"pmid": "15837967"}}
{"text": "Any subsequent trials of the HART regimen must address the issues that led to early closure, including slow accrual, logistics of HART, mucosal toxicity, and the fact that concurrent chemoradiotherapy now seems more effective than sequential treatment.", "user_data": {"pmid": "15837967"}}
{"text": "At an extended median follow-up of 27.0 months (range, 0-66.9 months), 319 (74.5%) patients in the fulvestrant group and 322 (76.1%) patients in the anastrozole group had died.", "user_data": {"pmid": "15937908"}}
{"text": "Prolonged survival was observed with both drugs, with 10-20% of patients still alive > 5 years after randomization.", "user_data": {"pmid": "15937908"}}
{"text": "The median overall survival was similar between treatments, being 27.4 months and 27.7 months in fulvestrant and anastrozole-treated patients, respectively (hazards ratio, 0.98; 95% confidence interval, 0.84-1.15; P = 0.809).", "user_data": {"pmid": "15937908"}}
{"text": "Fulvestrant continued to be well tolerated, and was associated with a significantly lower incidence of joint disorders compared with anastrozole (P = 0.0234).", "user_data": {"pmid": "15937908"}}
{"text": "In placebo treated men without prostate cancer there was an 8.3% median increase in PSA at month 24 compared with -59.5% in those who received dutasteride, using doubled values to correct for dutasteride treatment.", "user_data": {"pmid": "16600723"}}
{"text": "In those with prostate cancer these changes were 23.8% and -37.2%, respectively.", "user_data": {"pmid": "16600723"}}
{"text": "Using the upper PSA limit of 4 ng/ml sensitivity for prostate cancer in men receiving dutasteride vs placebo was 0.737 vs 0.804, while specificity was 0.671 vs 0.578.", "user_data": {"pmid": "16600723"}}
{"text": "Using a PSA increase from nadir of 0.8 ng/ml the sensitivity of dutasteride was 0.548 and its specificity was 0.795.", "user_data": {"pmid": "16600723"}}
{"text": "The 15-year actuarial locoregional recurrence rate was 7% for the q.d. arm and 12% for the b.i.d. arm (p=0.36).", "user_data": {"pmid": "16750325"}}
{"text": "The rates of severe acute toxicity were similar (4% for q.d. vs. 5% for b.i.d.), but moist desquamation developed in 42% of patients in the b.i.d. arm compared with 28% of the patients in the q.d. arm (p=0.16).", "user_data": {"pmid": "16750325"}}
{"text": "The 15-year actuarial rate of severe late RT complications did not differ between the two arms (6% for q.d. vs. 11% for b.i.d., p=0.54).", "user_data": {"pmid": "16750325"}}
{"text": "After 12 months, bone mineral density increased by 1.2% at the spine and 1.3% at the hip in women on risedronate vs. significant decreases for women in the placebo group of 0.9% at the spine and 0.8% at the hip (P < 0.01, difference between groups).", "user_data": {"pmid": "17047022"}}
{"text": "N-telopeptide cross-linked collagen type I, a marker of bone resorption, decreased by 19.3%, and N-terminal propeptide of type I procollagen, a marker of bone formation, decreased by 26.6% in participants on active therapy compared with increases in the control group.", "user_data": {"pmid": "17047022"}}
{"text": "Risedronate was well tolerated, and the retention rate was 95% at 1 yr.", "user_data": {"pmid": "17047022"}}
{"text": "In univariate analysis, a boost reduced local failure by a factor of 2 (P<0.0001).", "user_data": {"pmid": "17126434"}}
{"text": "Multivariate analysis showed local control increased with age (P=0.0003).", "user_data": {"pmid": "17126434"}}
{"text": "There was no evidence that the relative effect of a boost on local control depends on age (P=0.97) However in younger patients the 5-year local failure was higher, therefore the absolute reduction was greater.", "user_data": {"pmid": "17126434"}}
{"text": "If the threshold-age for boost treatment were set at 40 years, 8.4% of the study population would receive a boost, resulting in a 5-year local failure of 6.1% in the study population.", "user_data": {"pmid": "17126434"}}
{"text": "Changing the threshold-age to 60 years, 67% of the study population would receive a boost and the 5-year local failure would be reduced to 4.4%.", "user_data": {"pmid": "17126434"}}
{"text": "ORR was 42.6% for CAF compared with 53.1% for dofequidar + CAF, a 24.6% relative improvement and 10.5% absolute increase (P = .077).", "user_data": {"pmid": "17179098"}}
{"text": "There was a trend for prolonged progression-free survival (PFS; median 241 days for CAF v 366 days for dofequidar + CAF; P = .145).", "user_data": {"pmid": "17179098"}}
{"text": "In retrospectively defined subgroups, significant improvement in PFS in favor of dofequidar was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor.", "user_data": {"pmid": "17179098"}}
{"text": "Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF.", "user_data": {"pmid": "17179098"}}
{"text": "Treatment with dofequidar did not affect the plasma concentration of doxorubicin.", "user_data": {"pmid": "17179098"}}
{"text": "Among women under instruction, 864 breast cancers detected and 133 breast cancer deaths occurred while 896 breast cancers were detected and 130 deaths recorded in the control group.", "user_data": {"pmid": "17402204"}}
{"text": "The tumor size (P = 0.07), TNM stage (P = 0.39) and cumulative breast cancer mortality rate (P = 0.72) were not significantly different between the 2 groups.", "user_data": {"pmid": "17402204"}}
{"text": "However, more and smaller fibroadenomas were detected in the instruction group than in the control group (P< 0.01).", "user_data": {"pmid": "17402204"}}
{"text": "The P600 (47 patients) and P900 (45 patients) arms had response rates of 17.0% (95% confidence interval, 7.7-30.8%) and 15.6% (95% confidence interval, 6.5-29.5%) with approximately 50% stable disease per arm, median progression-free survival of 4.2 and 4.1 months, and median times to tumor progression of 4.2 and 4.6 months, respectively.", "user_data": {"pmid": "17575230"}}
{"text": "Both arms exhibited minimal toxicity (grade 3/4 neutropenia <20%, leukopenia <9%, and other toxicities <5%).", "user_data": {"pmid": "17575230"}}
{"text": "Tumor samples from 49 patients were assessed for the expression levels of 12 pemetrexed-related genes.", "user_data": {"pmid": "17575230"}}
{"text": "Folylpolyglutamate synthetase and thymidine phosphorylase correlated with efficacy.", "user_data": {"pmid": "17575230"}}
{"text": "Best response rates and median time to tumor progression for high versus low thymidine phosphorylase expression were 27.6% versus 6.3% (P = 0.023) and 5.4 versus 1.9 months (P = 0.076), and for folylpolyglutamate synthetase were 37.5% versus 10.0% (P = 0.115) and 8.6 versus 3.0 months (P = 0.019), respectively.", "user_data": {"pmid": "17575230"}}
{"text": "gamma-Glutamyl hydrolase expression correlated with grade 3/4 toxicities: 78.6% for high versus 27.3% for low gamma-glutamyl hydrolase (P = 0.024).", "user_data": {"pmid": "17575230"}}
{"text": "Of 1857 patients, 79 (4.3%) developed a syndrome of bowel wall injury (BWI, small or large) characterized by hospitalization for the management of severe diarrhea or dehydration and radiographic or endoscopic evidence of bowel wall thickening or ulceration.", "user_data": {"pmid": "17853393"}}
{"text": "Fifty-one (64.6%) of these adverse events occurred in patients treated with FLOX and 28 (35.4%) in those treated with FL (P < .01).", "user_data": {"pmid": "17853393"}}
{"text": "Enteric sepsis (ES), characterized by grade 3 or greater diarrhea and grade 4 neutropenia with or without proven bacteremia occurred in 22 patients treated with FLOX, versus 8 in those treated with FL (P = .01).", "user_data": {"pmid": "17853393"}}
{"text": "Patients >60 years were at higher risk for BWI after treatment with FLOX (6.7%) versus treatment with FL (2.9%, P < .01).", "user_data": {"pmid": "17853393"}}
{"text": "Female patients had a higher incidence of BWI with FLOX (9.1%) than with FL (3.9%, P < .01).", "user_data": {"pmid": "17853393"}}
{"text": "Severe gastrointestinal toxicity usually occurred during the third or fourth week on the first cycle of therapy, required hospitalization, and was managed with fluids, antidiarrheals, and antibiotics.", "user_data": {"pmid": "17853393"}}
{"text": "There were 5 deaths (0.3%) due to enteropathy, 2 related to ES and 3 related to both BWI and ES.", "user_data": {"pmid": "17853393"}}
{"text": "Seventy-one percent of patients resumed treatment with FL after recovery.", "user_data": {"pmid": "17853393"}}
{"text": "Compliance was excellent, with 7,286 questionnaires analyzed.", "user_data": {"pmid": "17947724"}}
{"text": "Baseline symptom prevalence ranged from 2% (vaginal bleeding) to 60% to 70% (bone/muscle aches and low energy).", "user_data": {"pmid": "17947724"}}
{"text": "There were no significant differences in vaginal bleeding, mood alteration, or low energy.", "user_data": {"pmid": "17947724"}}
{"text": "Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001).", "user_data": {"pmid": "17947724"}}
{"text": "Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03).", "user_data": {"pmid": "17947724"}}
{"text": "In both groups, the hot flash score peaked at 3 months and decreased thereafter.", "user_data": {"pmid": "17947724"}}
{"text": "At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane.", "user_data": {"pmid": "17947724"}}
{"text": "In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately.", "user_data": {"pmid": "18235123"}}
{"text": "The chemotherapy regimens resulted in similar EFS and overall survival.", "user_data": {"pmid": "18235123"}}
{"text": "There was a trend toward better EFS with the addition of MTP (P = .08).", "user_data": {"pmid": "18235123"}}
{"text": "The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% (P = .03).", "user_data": {"pmid": "18235123"}}
{"text": "The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96).", "user_data": {"pmid": "18235123"}}
{"text": "The objective response rate was 18% and 27.5% in group A and B, respectively (p = 0.413).", "user_data": {"pmid": "19729979"}}
{"text": "No statistically significant differences were demonstrated in terms of median overall survival and time to disease progression.", "user_data": {"pmid": "19729979"}}
{"text": "The rate and grade 3 and 4 neutropenia were higher in group B (23 vs. 3%).", "user_data": {"pmid": "19729979"}}
{"text": "Use of CEE resulted in mean increase in mammographic percent density of 1.6 percentage points (95% CI, 0.8 to 2.4) at year 1 compared with a mean decrease of 1.0 percentage point (95% CI, -1.7 to -0.4) in the placebo group (P < .001).", "user_data": {"pmid": "19901118"}}
{"text": "The effect persisted for 2 years, with a mean increase of 1.7 percentage points (95% CI, 0.7 to 2.7) versus a mean decrease of 1.2 percentage points (95% CI, -1.8 to -0.5; P < .001) in the hormone and placebo groups, respectively.", "user_data": {"pmid": "19901118"}}
{"text": "These effects were greater in women age 60 to 79 years (P = .03 for interaction across age).", "user_data": {"pmid": "19901118"}}
{"text": "The QoL questionnaires were completed by 37 pts (88%) in the DCT/CDDP arm and 39 pts (87%) in the VNR/CDDP one.", "user_data": {"pmid": "19910076"}}
{"text": "Baseline mean scores and rates at which pts failed to complete QoL assessment were similar in the two arms.", "user_data": {"pmid": "19910076"}}
{"text": "Global health status of the EORTC QLQ-C30 scale and specific symptoms control (LC13 module) improved during treatment without any statistically significant difference between the two arms.", "user_data": {"pmid": "19910076"}}
{"text": "Emotional functioning remained stable in both groups during treatment, whereas physical and role improved slightly.", "user_data": {"pmid": "19910076"}}
{"text": "In the DCT/CDDP arm 14 pts (33%; 95%CL 24-40%) had PR, and 10 (24%) SD for a 57% TGCR.", "user_data": {"pmid": "19910076"}}
{"text": "In the VNR/CDDP arm 12 pts (27%) achieved PR, 18 (41%) SD a 68% TGCR.", "user_data": {"pmid": "19910076"}}
{"text": "Differences were not statistically significant.", "user_data": {"pmid": "19910076"}}
{"text": "Median time-to-progression was 4.2 months in the DCT/CDDP arm and 4.5 months in the VNR/CDDP one, and median overall survival was 12.1 (range 1-26+ months) and 12.5 months (range 1-28+ months) for DCT/CDDP and VNR/CDDP arms, respectively.", "user_data": {"pmid": "19910076"}}
{"text": "Febrile neutropenia rate was higher in the VNR/CDDP arm (p=0.02) as well as G3-4 anemia (p=0.005) and G-CSF/EPO use (p=0.019).", "user_data": {"pmid": "19910076"}}
{"text": "ORR for patients randomly assigned to receive EC and ED were 42% and 47%, respectively (P = 0.63).", "user_data": {"pmid": "20089562"}}
{"text": "Median PFS [10.1 versus 10.3 months; hazard ratio (HR) 0.98; log-rank P = 0.38] and OS (19.9 versus 30.0 months; HR 0.663; log-rank P = 0.21) were comparable in both arms.", "user_data": {"pmid": "20089562"}}
{"text": "Although grade 3/4 leucopenia occurred more frequently with ED (81% versus 73%; P = 0.01), there were no significant differences in the incidence of febrile neutropenia and grade 3/4 infections.", "user_data": {"pmid": "20089562"}}
{"text": "Grade 3/4 non-haematologic toxicity was infrequent in both arms.", "user_data": {"pmid": "20089562"}}
{"text": "Congestive heart failure was observed in one patient in each arm.", "user_data": {"pmid": "20089562"}}
{"text": "A total of 80 patients were entered in this trial.", "user_data": {"pmid": "20147856"}}
{"text": "The primary end point of this study was response rate.", "user_data": {"pmid": "20147856"}}
{"text": "The response rates of arm A and arm B were 22.0 and 28.9%, respectively (p = 0.606).", "user_data": {"pmid": "20147856"}}
{"text": "Median time to treatment failure in arm A was 3.6 months and 4.8 months in arm B. Median time to progression in arm A was 4.1 months and 5.5 months in arm B. Median survival time in arm A and arm B was 15.5 months and 18.8 months, respectively.", "user_data": {"pmid": "20147856"}}
{"text": "The toxicity profile was relatively mild and did not differ very much between two arms.", "user_data": {"pmid": "20147856"}}
{"text": "Women in the intervention group were more knowledgeable (mean score out of 10, 7.35 vs 6.27, p<0.001) and were more likely to have made a decision (82% vs 61% p<0.001).", "user_data": {"pmid": "20149953"}}
{"text": "Of those who made a decision, women in the intervention group were less likely to start screening now (52% vs 65% p=0.05).", "user_data": {"pmid": "20149953"}}
{"text": "There was no significant difference in the proportion of women who made an informed choice (71% intervention group vs 64% control group, p=0.24).", "user_data": {"pmid": "20149953"}}
{"text": "The DA was helpful, balanced and clear, and did not make women anxious.", "user_data": {"pmid": "20149953"}}
{"text": "Comparative analysis of the first conducted and randomly assigned 55 cases revealed a significantly higher diagnostic yield for cryobiopsy compared with forceps biopsy (89.1% vs 65.5%, P < .05).", "user_data": {"pmid": "20226474"}}
{"text": "In this cohort, quantitative image analysis showed significantly larger biopsies regarding size and artifact-free tissue sections for cryobiopsy compared with forceps biopsy (P < .0001).", "user_data": {"pmid": "20226474"}}
{"text": "The overall diagnostic yield of cryobiopsy was 89.5%.", "user_data": {"pmid": "20226474"}}
{"text": "Mild bleeding occurred in 11 cases (3.7%), moderate bleeding occurred in 3 cases (1.0%), and severe bleeding occurred in 1 case (0.3%).", "user_data": {"pmid": "20226474"}}
{"text": "Demographic and clinical profiles of both groups were not statistically different.", "user_data": {"pmid": "20506785"}}
{"text": "The tented patients had statistically significant reduction of mean duration of air leak in days (4.9 +/- 1.79 vs 8.2 +/- 4.2), the number of days of a chest tube duration (7.3 +/- 1.14 vs 12.46 +/- 3.6), the length of postoperative in-hospital stay in days (9.4 +/- 1.86 vs 13.6 +/- 2.49), and the hospital stay cost per patient (leva, 3840 +/- 298 vs 5160 +/- 3890).", "user_data": {"pmid": "20506785"}}
{"text": "Logistic regression analyses showed that no having creation a pleural tent procedure was the most significant predictive factor of the occurrence and duration of prolonged air leaks.", "user_data": {"pmid": "20506785"}}
{"text": "A greater reduction in the duration of air leaks was observed before postoperative day 4 in group 1, and logistic regression analysis showed that having a pleural tent procedure was the most significant predictive factor of air leaks that persisted for less than 4 days.", "user_data": {"pmid": "20506785"}}
{"text": "Thirty-seven and 40 patients were randomly assigned to study arm and control arm.", "user_data": {"pmid": "20673485"}}
{"text": "The local recurrence rates were 32.4% and 28.2% respectively (P = 0.80); the isolated nodal failure (INF) rates were 3.0% and 2.6% respectively (P = 0.91); all INF sites were in the ipsilateral supraclavicular fossa.", "user_data": {"pmid": "20673485"}}
{"text": "Medastinal N3 disease was the risk factor for INF (P = 0.02, OR = 14.13, 95% CI: 1.47-136.13).", "user_data": {"pmid": "20673485"}}
{"text": "During radiotherapy, grade I, II weight loss was observed in 29.4%, 5.9% and 56.4%, 7.7% patients respectively (P = 0.04).", "user_data": {"pmid": "20673485"}}
{"text": "Grade 0-I and II-III late pulmonary injury was developed in 97.1%, 2.9% and 86.4%, 15.4% patients respectively (P = 0.07).", "user_data": {"pmid": "20673485"}}
{"text": "Median survival time was 22.1 months and 26.9 months respectively.", "user_data": {"pmid": "20673485"}}
{"text": "The 1 to 3-year OS were 77.9%, 44.4%, 37.3% and 75.8%, 56.3%, 41.7% respectively (P = 0.79).", "user_data": {"pmid": "20673485"}}
{"text": "There were no significant differences between treatment groups for mean change in Fridericia's correction of QT during the trial.", "user_data": {"pmid": "20952020"}}
{"text": "Markedly abnormal Fridericia's correction of QT values (500 milliseconds or greater) were observed in only a small number of subjects by treatment group, that is 2 (less than 1%) in the pooled degarelix group and 2 (1%) in the leuprolide group.", "user_data": {"pmid": "20952020"}}
{"text": "Supraventricular arrhythmias were the most common type of arrhythmias, affecting 2% of subjects in the pooled degarelix group and 4% in the leuprolide group.", "user_data": {"pmid": "20952020"}}
{"text": "Other arrhythmias occurred in 1% or less of subjects by treatment group.", "user_data": {"pmid": "20952020"}}
{"text": "The most frequently reported cardiac disorder was ischemic heart disease, which occurred in 4% of subjects treated with degarelix and 10% of those on leuprolide.", "user_data": {"pmid": "20952020"}}
{"text": "Cox proportional hazard ratio estimates for selected baseline covariates showed a significantly increased risk of cardiovascular events by age (p=0.0459) and systolic blood pressure (p=0.0061).", "user_data": {"pmid": "20952020"}}
{"text": "Denosumab was superior to zoledronic acid in delaying time to first on-study SRE (hazard ratio, 0.82; 95% CI, 0.71 to 0.95; P = .01 superiority) and time to first and subsequent (multiple) on-study SREs (rate ratio, 0.77; 95% CI, 0.66 to 0.89; P = .001).", "user_data": {"pmid": "21060033"}}
{"text": "Reduction in bone turnover markers was greater with denosumab.", "user_data": {"pmid": "21060033"}}
{"text": "Overall survival, disease progression, and rates of adverse events (AEs) and serious AEs were similar between groups.", "user_data": {"pmid": "21060033"}}
{"text": "An excess of renal AEs and acute-phase reactions occurred with zoledronic acid; hypocalcemia occurred more frequently with denosumab.", "user_data": {"pmid": "21060033"}}
{"text": "Osteonecrosis of the jaw occurred infrequently (2.0%, denosumab; 1.4%, zoledronic acid; P = .39).", "user_data": {"pmid": "21060033"}}
{"text": "Despite over-accrual of 475 patients, the trial matured with only 324 of 385 planned TtP events due to patient discontinuations.", "user_data": {"pmid": "21084429"}}
{"text": "Human epidermal growth factor receptor 2 status was not captured in this study.", "user_data": {"pmid": "21084429"}}
{"text": "More CD patients (28%) discontinued due to AEs than GD patients (18.0%, P = 0.009).", "user_data": {"pmid": "21084429"}}
{"text": "TtP [hazard ratio (HR) = 1.101, 95% confidence interval (CI) 0.885-1.370, P = 0.387] and OS (HR = 1.031, 95% CI 0.830-1.280, P = 0.785) were not significantly different comparing GD and CD.", "user_data": {"pmid": "21084429"}}
{"text": "ORR was not statistically different (P = 0.239) comparing GD (72 of 207, 34.8%) and CD (78 of 191, 40.8%).", "user_data": {"pmid": "21084429"}}
{"text": "TtP, OS, and ORR were not significantly different comparing crossover groups.", "user_data": {"pmid": "21084429"}}
{"text": "GD caused greater fatigue, hepatotoxicity, neutropenia, and thrombocytopenia but not febrile neutropenia; CD caused more hand-foot syndrome, gastrointestinal toxicity, and mucositis.", "user_data": {"pmid": "21084429"}}
{"text": "In stratum 1 (n = 206), the PFS HR (gefitinib:placebo) was 0.84 (95% CI, 0.59-1.18; median PFS 10.9 versus 8.8 months).", "user_data": {"pmid": "21220480"}}
{"text": "In the stratum 1 endocrine therapy-na\u00efve subset (n = 158) the HR was 0.78 (95% CI, 0.52-1.15), and the prior endocrine-treated subgroup (n = 48) 1.47 (95% CI, 0.63-3.45).", "user_data": {"pmid": "21220480"}}
{"text": "In stratum 1, CBRs were 50.5% with gefitinib and 45.5% with placebo.", "user_data": {"pmid": "21220480"}}
{"text": "In stratum 2 (n = 84), CBRs were 29.2% with gefitinib and 31.4% with placebo.", "user_data": {"pmid": "21220480"}}
{"text": "Biomarker analysis suggested that in stratum 1 there was greater benefit with gefitinib in patients who were ER-negative or had lower levels of ER protein.", "user_data": {"pmid": "21220480"}}
{"text": "The five-year actuarial rates of cancer recurrence at any site and of distant metastases in the radiotherapy-first group and the chemotherapy-first group were 38 percent and 31 percent (P = 0.17) and 36 percent and 25 percent (P = 0.05), respectively.", "user_data": {"pmid": "8614420"}}
{"text": "Overall survival was 73 percent and 81 percent (P = 0.11), respectively.", "user_data": {"pmid": "8614420"}}
{"text": "The five-year crude rates of first recurrence according to site in the radiotherapy-first and chemotherapy-first groups, respectively, were 5 percent and 14 percent for local recurrence and 32 percent and 20 percent for distant or regional recurrence or both.", "user_data": {"pmid": "8614420"}}
{"text": "This difference in the pattern of recurrence was of borderline statistical significance (P = 0.07).", "user_data": {"pmid": "8614420"}}
{"text": "There was no significant difference in survival whether treatment was administered to the prostate or prostate and pelvic lymph nodes.", "user_data": {"pmid": "9531360"}}
{"text": "The SL group had greater 12-year survival than the LAG group (48% vs. 38%, p = 0.02).", "user_data": {"pmid": "9531360"}}
{"text": "Disease-free survival was statistically significant, with 38% for the SL group vs. 26% for the LAG group (p = 0.003).", "user_data": {"pmid": "9531360"}}
{"text": "Bone metastasis was less common in the SL group (14%) than the LAG group (27%) (p = 0.003).", "user_data": {"pmid": "9531360"}}
{"text": "In the 1202 men studied, 361 cases of prostate cancer were diagnosed.", "user_data": {"pmid": "9697788"}}
{"text": "Both PSA-D and PSA-T showed a significantly higher area under the ROC curve (0.77 and 0.79, respectively) than PSA alone (area 0.65).", "user_data": {"pmid": "9697788"}}
{"text": "There was no significant difference between PSA-D and PSA-T. ", "user_data": {"pmid": "9697788"}}
{"text": "The use of a PSA-D threshold value of 0.10 ng/mL/cc would have avoided 28% of biopsies at the cost of 10% of detectable cancers.", "user_data": {"pmid": "9697788"}}
{"text": "A PSA-D threshold of 0.15 ng/mL/cc would have avoided 73.8% of biopsies at the cost of not diagnosing 43.8% of detectable cancers.", "user_data": {"pmid": "9697788"}}
{"text": "Lymphocysts appeared in 23/61 patients (38%) in total.", "user_data": {"pmid": "9701205"}}
{"text": "In the \"closure\" group, the incidence was 52% (16/31), but in the \"no-closure\" group it was only 23% (7/30); the incidence in the \"no-closure\" group was significantly lower (P < 0.05).", "user_data": {"pmid": "9701205"}}
{"text": "The incidence of postoperative fever was 17% (5/30) in the \"no-closure\" group, which was lower than that in the \"closure\" group (42%, 13/31), but not significantly so (P < 0.1).", "user_data": {"pmid": "9701205"}}
{"text": "No patients in the \"no-closure\" group required surgical procedures such as needle aspiration or cyst drainage.", "user_data": {"pmid": "9701205"}}
